⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28823448 | 0.97 | — | — | |
| Ethylene SCHEMBL28883508 | 0.94 | — | — | |
| Methyl Alcohol SCHEMBL21630012 | 0.91 | — | — | |
| Methylamine SCHEMBL4819184 | 0.91 | — | — | |
| SCHEMBL16390982 | 0.89 | — | — | |
| Boric Acid SCHEMBL8755222 | 0.87 | HSD17B1 (0.40) | — | |
| Pyridine SCHEMBL102868 | 0.84 | ASIC3 (0.47) | — | |
| Ethylamine SCHEMBL4431062 | 0.84 | — | — | |
| Acetic Acid SCHEMBL9941297 | 0.83 | KMO (0.47) | — | |
| SCHEMBL10324727 | 0.81 | LMNA (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020030095-A1 | PHARMACEUTICAL COMPOSITION CONTAINING META-DIAMIDE COMPOUND AND USE THEREOF | 上海泰禾国际贸易有限公司 | 2020-02-13 | — | — | WO | claimed |
| WO-2020030093-A1 | PHARMACEUTICAL COMPOSITION CONTAINING M-DIAMIDE COMPOUND AND APPLICATION THEREOF | 上海泰禾国际贸易有限公司 | 2020-02-13 | — | — | WO | claimed |
| EP-2419429-B1 | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | claimed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | claimed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | claimed |
| EP-2419429-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-22 | — | — | EP | claimed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | claimed |
| US-20050148588-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2005-07-07 | — | — | US | claimed |
| US-6872735-B2 | LFA-1 antagonist compounds | GENENTECH, INC. (US) | 2005-03-29 | — | — | US | claimed |
| US-20040058968-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2004-03-25 | — | — | US | claimed |
| US-6667318-B2 | Antiinflammatory agents; autoimmune disease | GENENTECH, INC. | 2003-12-23 | — | — | US | claimed |
| US-20020119994-A1 | LFA-1 Antagonist compounds | GENENTECH, INC | 2002-08-29 | — | — | US | claimed |
| US-12558350-B2 | Compositions and methods for treatment | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-02-24 | — | — | US | disclosed |
| US-20240344061-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240254462-A1 | COMPOSITIONS AND METHODS FOR MODULATING SECRETED FRIZZLED RECEPTOR PROTEIN 1 (SFRP1) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-11987791-B2 | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression | OMEGA THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-5659022-A | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids | EPOCH PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1994006793-A1 | 3,3'-DISUBSTITUTED-1,3-DIHYDRO-2H-PYRROLO[2,3-b]HETEROCYCLIC-2-ONE USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS OF MAN | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5278162-A | Learning enhancement | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0317416-A1 | Process for the preparation of 1-chloro-5-alkyl isoquinolines condensed with aromatic groups, the products so obtained and their use as medicines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-05-24 | — | — | EP | disclosed |